J.B. Chemicals & Pharmaceuticals Limited has scheduled its 50th Annual General Meeting (AGM) for June 17, 2026, at 3:00 p.m. IST via Video Conferencing. The meeting will transact business including the adoption of financial statements for the year ended March 31, 2026, and the declaration of dividends. Shareholders holding shares as on the record date of May 29, 2026, will be eligible to receive the dividend payout.

The board has proposed a final dividend of ₹9.30 per equity share for the financial year 2025-26. Additionally, the meeting will seek confirmation for an interim dividend of ₹12.70 per equity share already paid during the financial year. If approved, the final dividend is scheduled to be paid on or after June 19, 2026, subject to tax deduction at source as per the Income Tax Act, 2025.

Agenda and Appointments

The AGM will consider the adoption of the audited financial statements and consolidated financial statements for the year ended March 31, 2026. Shareholders will also vote on the re-appointment of Mr. Amal Kelshikar (DIN: 06378987), who retires by rotation and is eligible for re-appointment. Mr. Kelshikar currently oversees the India business of Torrent Pharmaceuticals Limited and brings over 32 years of experience in strategic planning and marketing.

Annual Report and Notice Dispatch

In compliance with Regulation 36(1)(a) and 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has dispatched the Notice of the 50th AGM along with the Integrated Annual Report for FY 2025-26. Members with registered email addresses received these documents electronically. For shareholders whose email addresses are not registered with the Registrar & Share Transfer Agent or Depository Participants, the company has dispatched letters providing the web-link to access the Integrated Annual Report. The company has requested these shareholders to update their email details to ensure easy access to future documents.

E-Voting and Participation Details

Remote e-voting facilities will be available from June 14, 2026, at 9:00 a.m. to June 16, 2026, at 5:00 p.m. Shareholders holding shares as on the cut-off date of June 10, 2026, are eligible to cast their votes. The company has engaged Central Depository Services (India) Limited (CDSL) to facilitate the electronic voting process.

Shareholders holding physical shares are requested to ensure their KYC details, including PAN and bank account information, are updated to receive dividends electronically. The company has advised members to utilize the Electronic Clearing System (ECS) for seamless dividend receipt.

J.B. Chemicals & Pharmaceuticals Limited reported a net profit of INR 70,947 Lakhs for the financial year ended March 31, 2026, according to its Business Responsibility and Sustainability Report filed on May 25, 2026. The company achieved consolidated revenue from operations of INR 4,14,779 Lakhs, reflecting steady growth compared to the previous year. The Board of Directors recommended a final dividend of INR 9.30 per equity share for the fiscal year.

The company maintained a strong operational safety record, reporting zero fatalities across all manufacturing plants and locations for the reporting period. JB Pharma also recorded zero Lost Time Injury Frequency Rate (LTIFR) and no cases of occupational disease. The organization spent 0.24% of its total revenue on measures towards the well-being of employees and workers.

Environmental Performance

JB Pharma made significant progress in its environmental sustainability initiatives during FY26. The company substituted over 43% of its total energy consumption with renewable sources, exceeding the previous year's figure of 37%. Total energy consumed stood at 635,119.6 Giga Joules (GJ), with renewable sources accounting for 43.70% of the total energy mix.

The company achieved Zero Liquid Discharge (ZLD) across all manufacturing sites. Total water consumption was recorded at 307,507.11 kiloliters (KL), while water discharge amounted to 4,346.32 KL. JB Pharma reported total Scope 1 emissions of 5,238.92 MT of CO2e and Scope 2 emissions (market-based) of 54,647.26 MT of CO2e.

Waste Management

The company managed a total of 3,276.09 metric tonnes (MT) of waste across its operations. A significant portion of the waste was recovered through recycling and other recovery operations, totaling 2,497.76 MT, which represents 76.24% of the total waste generated. The waste disposed via incineration and landfilling was 580.87 MT.

Social and Governance Metrics

JB Pharma reported a total workforce of 7,906 employees and workers. The gross wages paid to females constituted 10.28% of the total wages paid by the entity. The company confirmed zero complaints regarding sexual harassment (POSH) and zero incidents of discrimination during the year.

DNV Business Assurance India Private Limited provided reasonable assurance for the BRSR Core indicators and limited assurance for the non-financial sustainability disclosures. The assurance covered operations across 8 manufacturing plants, 1 corporate office, 1 registered office, 5 regional offices, 1 R&D centre, 26 C&F locations, and 5 warehouses.